Antinuclear antibodies in patients on acebutolol.

Antinuclear antibodies in rosacea patients

INTRODUCTION Rosacea is a common inflammatory disorder, characterized by a spectrum of facial manifestations. The clinical similarity to other dermatoses, like lupus erythematosus, might lead to misdiagnosis, particularly in patients with elevated antinuclear antibody titers. AIM To assess the frequency, titer and specificity of antinuclear antibodies in rosacea patients and correlate these f...

Ocular, systemic and antinuclear antibody changes with acebutolol.

A group of 29 hypertensive patients were studied for side effects of acebutolol. An antinuclear antibody titre of >/=1/64 developed in 23 per cent of patients during a 12-month course of treatment. Full ophthalmic examination before and after the treatment period showed a statistically significant increase in tear secretion at one year. One patient had a slight worsening of her psoriasis. No pa...

Antinuclear Antibodies

knowledge of gene regulation, particularly in neoplastic cells, this deficit is striking. With our current understanding of chromosomal translocations, point mutations, and gene amplification in tumor cells, it is surprising to read that there is ". . . no difference between cancer and normal DNA . . ." (p. 130). The author spends a fair amount of time discussing possible mechanisms for the car...

Antinuclear antibodies in patients receiving non-practolol beta-blockers.

Antinuclear antibodies (ANA) were found in 54 (7.0%) out of 767 treated hypertensive patients compared with 59 (2.4%) out of 2470 healthy controls. Inclusion of a non-practolol beta-blocker in the treatment regimen did not significantly affect the incidence of ANA. ANA was found in significantly more patients being treated with methyldopa (13.0%) than patients receiving other hypotensive agents...

Antinuclear antibodies in systemic sclerosis